Ultomiris (Ravulizumab-cwvz) for Myasthenia Gravis

Overview
Ultomiris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for treating adults living with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. Ultomiris is also referred to by its drug name, ravulizumab-cwvz.

Ultomiris is a member of a class of drugs called monoclonal antibodies. It’s believed to work by disrupting communication between nerves and muscles in people with myasthenia gravis.

How do I take it?
Prescribing information states that Ultomiris is administered via an IV or subcutaneous (under the skin) injection. For people with generalized myasthenia gravis, the label recommends that dosages be administered intravenously once every eight weeks, starting two weeks after the first dose. Dosage size is determined based on the recipient’s body weight.

Side effects
Common side effects listed for Ultomiris in people with generalized myasthenia gravis include diarrhea and upper respiratory tract infection.

Rare but serious side effects for Ultomiris include serious meningococcal infections and other types of infections, infusion-related reactions including anaphylaxis (severe allergic reaction), lower back pain, decrease or increase in blood pressure, pain in the arms and legs, drug hypersensitivity, unpleasant taste in the mouth, and drowsiness.

For more details about this treatment, visit:

Ultomiris — Alexion Pharmaceuticals
https://ultomiris.com/

Ultomiris — Drugs.com
https://www.drugs.com/ultomiris.html